Showing 1 - 20 results of 73 for search '"erythropoietin"', query time: 0.05s Refine Results
  1. 1
  2. 2

    Erythropoietin: from erythropoiesis to cardioprotection by Liermis Michael Dita Salabert, Ivis Mendoza Hernández, Rafael Alejandro Gómez Baute, Elena García López, Lázaro E. de la Cruz Avilés, Aramis Núñez Quintana

    Published 2010-08-01
    “…The identification of erythropoietin receptor in hematopoietic tissues, including the heart, as well as its marked cardioprotective effect during ischemia have led to the hypothesis that erythropoietin may be able to prevent anthracycline-induced cardiomyopathy. …”
    Get full text
    Article
  3. 3

    The Antioxidant Effect of Erythropoietin on Thalassemic Blood Cells by Johnny Amer, Mutaz Dana, Eitan Fibach

    Published 2010-01-01
    “…Because of its stimulating effect on RBC production, erythropoietin (Epo) is used to treat anemia, for example, in patients on dialysis or on chemotherapy. …”
    Get full text
    Article
  4. 4

    THE ROLE OF ERYTHROPOIETIN IN TREATMENT OF ANEMIA IN CANCER PATIENTS by P. G. Berezin, V. V. Milovanov, A. A. Ivannikov

    Published 2017-06-01
    “…This article analyzes the efficacy of recombinant erythropoietin — Epoetin-theta in the treatment of patients with NON — myeloid tumors and CRF (chronic renal failure) in cancer patients. …”
    Get full text
    Article
  5. 5
  6. 6

    Polycythemia with Renal Cell Carcinoma and Normal Erythropoietin Level by Jonathan Kopel, Pranav Sharma, Irfan Warriach, Sriman Swarup

    Published 2019-01-01
    “…Though previously reported, the concomitant finding of an AAA with renal cell carcinoma with a normal erythropoietin levels is surprising. Given the surgical complications associated with concomitant conditions with renal cell carcinoma, further investigation into paraneoplastic syndromes secondary to renal cell carcinoma remains open to investigation.…”
    Get full text
    Article
  7. 7

    Erythropoietin, Forkhead Proteins, and Oxidative Injury: Biomarkers and Biology by Kenneth Maiese, Jinling Hou, Zhao Zhong Chong, Yan Chen Shang

    Published 2009-01-01
    “…In particular, both the growth factor and cytokine erythropoietin (EPO), and members of the mammalian forkhead transcription factors of the O class (FoxOs), may offer the greatest promise for new treatment regimens, since these agents and the cellular pathways they oversee cover a range of critical functions that directly influence progenitor cell development, cell survival and degeneration, metabolism, immune function, and cancer cell invasion. …”
    Get full text
    Article
  8. 8
  9. 9

    Engineering synthetic signaling receptors to enable erythropoietin-free erythropoiesis by Aadit P. Shah, Kiran R. Majeti, Freja K. Ekman, Sridhar Selvaraj, Devesh Sharma, Roshani Sinha, Eric Soupene, Prathamesh Chati, Sofia E. Luna, Carsten T. Charlesworth, Travis McCreary, Benjamin J. Lesch, Tammy Tran, Simon N. Chu, Matthew H. Porteus, M. Kyle Cromer

    Published 2025-01-01
    “…Ex vivo manufacturing of red blood cells (RBCs) from universal donor cells offers a potential solution, yet the high cost of recombinant cytokines remains a barrier. Erythropoietin (EPO) signaling is crucial for RBC development, and EPO is among the most expensive media components. …”
    Get full text
    Article
  10. 10
  11. 11
  12. 12

    Recombinant human erythropoietin, and myocardial and cerebral acute ischemia: implications for clinical use. by Rafael Alejandro Gómez Baute, Liermis Dita Salabert, Yaney González Yglesias, Tamara Guerra Alfonso, Maritza Cabrera Zamora

    Published 2010-07-01
    “…Recombinant human erythropoietin has been used for more than two decades in clinical practice with promising results in the treatment of anemia associated with chronic renal insufficiency and in patients with cancer. …”
    Get full text
    Article
  13. 13

    Defective Slc7a7 transport reduces erythropoietin compromising erythropoiesis by Judith Giroud-Gerbetant, Fernando Sotillo, Gonzalo Hernández, Irene Ruano, David Sebastián, Joana Fort, Mayka Sánchez, Günter Weiss, Neus Prats, Antonio Zorzano, Manuel Palacín, Susanna Bodoy

    Published 2025-01-01
    “…Further investigation indicated that defective erythropoiesis is linked to impaired erythropoietin production in the kidney and subsequent iron overload. …”
    Get full text
    Article
  14. 14
  15. 15

    Nonhematopoietic Variants of Erythropoietin in Ischemic Stroke: Need for Step-Wise Proof-of-Concept Studies by Dirk M. Hermann

    Published 2010-01-01
    “…Neuroprotective, but not hematopoietic, variants of erythropoietin (EPO), such as Neuro-EPO, are promising candidates for treatment in the acute and subacute stroke phase. …”
    Get full text
    Article
  16. 16

    Effects of Low-Flux and High-Flux Dialysis Membranes on Erythropoietin Responsiveness in Hemodialysis Patients by Walid A. R. Abdelhamid, Mohamed M. Soliman, Ayman R. A. El-Hameed

    Published 2022-01-01
    “…Inadequate data have described the efficiency of high-flux dialysis in promoting erythropoietin responsiveness in CKD patients in the Middle East. …”
    Get full text
    Article
  17. 17

    Impact of an Interleukin-1 Receptor Antagonist and Erythropoietin on Experimental Myocardial Ischemia/Reperfusion Injury by Christina Grothusen, Angelika Hagemann, Tim Attmann, Jan Braesen, Ole Broch, Jochen Cremer, Jan Schoettler

    Published 2012-01-01
    “…We compared the impact of the interleukin-1 receptor antagonist Anakinra and erythropoietin on myocardial ischemia/reperfusion injury. …”
    Get full text
    Article
  18. 18
  19. 19

    The Nasal Route as a Potential Pathway for Delivery of Erythropoietin in the Treatment of Acute Ischemic Stroke in Humans by Julio Cesar García-Rodríguez, Iliana Sosa Teste

    Published 2009-01-01
    “…Using the intranasal delivery system, researchers have demonstrated neuroprotective effects in different animal models of stroke using erythropoietin (EPO) as a neuroprotector or other different types of EPO without erythropoiesis-stimulating activity. …”
    Get full text
    Article
  20. 20

    Visual-Evoked-Response-Supported Outcome of Intravitreal Erythropoietin in Management of Indirect Traumatic Optic Neuropathy by Mohammad Ahmad Rashad, Ahmed Abdel Meguid Abdel Latif, Hazem A. Mostafa, Samah Mahmoud Fawzy, Mahmoud Abdel Meguid Abdel Latif

    Published 2018-01-01
    “…Investigating the efficacy of intravitreal injection of erythropoietin (EPO) in managing indirect traumatic optic neuropathy (ITON) of different durations. …”
    Get full text
    Article